A comprehensive overview of CRISPR/Cas 9 technology and application thereof in drug discovery. Issue 10 (21st September 2022)

• Record Type: Journal Article
• Authors: Khurana, Amit; Sayed, Nilofer; Singh, Vishakha; Khurana, Isha; Allawadhi, Prince; Rawat, Pushkar Singh; Navik, Umashanker; Pasumarthi, Sravan Kumar; Bharani, Kala Kumar; Weiskirchen, Ralf
• Other Names: Rose‐John Stefan guestEditor.; Weiskirchen Ralf guestEditor.
• Is Part Of: Journal of cellular biochemistry. Volume 123:Issue 10(2022)
• Page Start: 1674
• Page End: 1698
• Publication Date: 2022-09-21
• Subjects: CRISPR/Cas9 -- drug discovery -- gene silencing -- genome editing -- RNA -- transfection; Cytochemistry -- Periodicals; 572
• DOI: 10.1002/jcb.30329
• Languages: English
• ISSNs: 0730-2312

Abstract

Abstract: Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)‐Cas technology possesses revolutionary potential to positively affect various domains of drug discovery. It has initiated a rise in the area of genetic engineering and its advantages range from classical science to translational medicine. These genome editing systems have given a new dimension to our capabilities to alter, detect and annotate specified gene sequences. Moreover, the ease, robustness and adaptability of the CRISPR/Cas9 technology have led to its extensive utilization in research areas in such a short period of time. The applications include the development of model cell lines, understanding disease mechanisms, discovering disease targets, developing transgenic animals and plants, and transcriptional modulation. Further, the technology is rapidly growing; hence, an overlook of progressive success is crucial. This review presents the current status of the CRISPR–Cas technology in a tailor‐made format from its discovery to several advancements for drug discovery alongwith future trends associated with possibilities and hurdles including ethical concerns.